Benign Conditions

Preoperative urodynamic testing in women undergoing surgery for uncomplicated, stress-predominant urinary incontinence commonly results in a change in clinical diagnosis.

The FDA recently approved oxybutynin transdermal (Oxytrol for Women) over-the-counter treatment for overactive bladder in women ages 18 years and older.

Urologists discuss the treatments that have most affected their practices.

Exposure to a desert environment increases lithogenic risk, but the effect is the result of unanticipated changes in excretion of lithogenic material, according to a recent study.

Intradetrusor injections of onabotulinumtoxinA (Botox) do not significantly reduce urinary frequency in patients with refractory overactive bladder secondary to BPH, results from a two-institution, placebo-controlled study indicate.